NICE concludes decision for two Alzheimer’s treatments
The committee’s final draft guidance cited high-cost as a key…
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.